Trial Profile
A Prospective Randomized Study on the Efficacy and Safety of the Prophylactic Use of Rituximab, Added to Standard Immunosuppressive Treatment in Comparison With Standard Immunosuppressive Treatment Alone in Renal Transplantation.
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 09 Feb 2022
Price :
$35
*
At a glance
- Drugs Rituximab (Primary)
- Indications Renal transplant rejection
- Focus Registrational; Therapeutic Use
- 03 May 2017 Results (n=246) assessing the effects of rituximab as a single-agent induction therapy on pre-existent or de novo DSA after renal transplantation, presented at the 2017 American Transplant Congress.
- 19 Jun 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 22 May 2013 Interim results presented at the American Transplant Congress - 13th Joint Congress of the American Society of Transplant Surgeons and the American Society of Transplantation.